DUBLIN–(BUSINESS WIRE)–The “Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2028” report has been added to ResearchAndMarkets.com’s offering.
The technological advancements in drug delivery have led to innovation of transdermal patches. The transdermal skin patches are articulated to deliver the active ingredients of drugs across skin into the systemic blood circulation in a continued or measured mode through diffusion. Apart from being convenient to patients and non-invasive, transdermal patches offer other advantages such as circumventing first-pass digestion and avoidance of gastric/enzymatic degradation. The transdermal patches are currently being commercialized as hassle-free, convenient, and durable products. These patches can be worn seven days, depending on their therapeutic indication.
The promising response of transdermal patches in the global market has further surged the further research and development in this sector. For instance in 2019, US FDA has approved Secuado, which is the first transdermal patch to treat Schizophrenia. Further in 2021, Gedeon Richter UK has announced that it has become marketing authorization holder (MAH) for Evra, a once weekly contraception for women of fertile age and the only transdermal contraceptive patch licensed in UK. The rising product launches in the global market will have a positive impact on the growth of market.
The pipeline for global transdermal patches is crowded, which suggests positive future of these patches in forthcoming years. For instance, recent clinical trial from Starton Therapeutics showed the promising results of STAR-LLD continuous delivery transdermal patch containing lenalidomide in a non-GLP rabbit pharmacokinetic (PK) and skin irritation study. Moreover, US FDA has also assigned a Prescription Drug User Fee Act target date of March 11, 2022 for the new drug application for Aldarity (donepezil transdermal system) for the treatment of patients with dementia due to mild, moderate, and severe Alzheimer disease. Aldarity is a once weekly transdermal formulation of donepezil that is designed to be worn for 7 days with consistent adhesion. These rising trends will propel the growth of market during the forecast period.
Currently, vaccine segment doesn’t have any transdermal patch showing that this area has lots of untapped opportunities for pharmaceutical companies. Several ongoing clinical trials are evaluating novel vaccine patch for influenza, HIV, COVID-19, and others. Recently in 2022, Institut Pasteur Korea (IPK) announced a research service agreement executed with Juvic Inc. for the joint development of microneedle based influenza vaccines. Merging Juvic’s microneedle production technology and IPK’s vaccine research and development capabilities, this collaboration is expected to facilitate the development of a microneedle influenza vaccine patch. Notably, the microneedle-based vaccine not only reduces the pain dramatically during vaccination but also can be distributed at room-temperature.
The global transdermal patch market is expected to witness high growth rates which is due to presence of key players and established healthcare infrastructure. Further beneficial government initiatives and an increase in the number of research partnerships are also expected to increase the market growth during the forecast period. Besides, high adoption rate of advance technologies is also expected to impel the growth of market in the region. As per our report findings, the global transdermal patch market is expected to surpass US$ 20 Billion by 2028.
Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2028 Report Highlights:
- Research Methodology
- Global & Regional Transdermal Path Market Outlook
- Global Transdermal Patch Market Opportunity > USD 20 Billion
- Clinical Trials Insight By Company, Indication, Drug Molecule & Phase
- Comprehensive Insight On 60 Transdermal Patch Available Commercially
- Comprehensive Insight On 80 Transdermal Patch In Clinical Trials By Phase
- Transdermal Patch Dosage & Price Availability By Indication
- Competitive Landscape
Key Topics Covered:
1. Introduction to Transdermal Patch
2. Transdermal Patches Classification
3. Mechanism of Transdermal Patch Drug Delivery
4. Global Transdermal Patch Market Outlook
5. Global Transdermal Patch Market Trends by Region
6. Transdermal Patches for Cardiovascular Diseases – Market Availability, Dosage & Price Analysis
7. Opioid Drug Containing Transdermal Patches – Market Availability, Dosage & Price Analysis
8. Transdermal Patch in Hormonal Therapy – Market Availability, Dosage & Price Analysis
9. Transdermal Patches for Neurological Disorders – Market Availability, Dosage & Price Analysis
10. Transdermal Patches for Other Conditions – Market Availability, Dosage & Price Analysis
11. Global Transdermal Patch Clinical Pipeline Overview
12. Global Patch Clinical Pipeline By Company, Indication & Phase
13. Marketed Transdermal Patch Clinical Insight
14. Global Transdermal Patch Market Dynamics
15. Global Transdermal Patch Market Future Outlook 2028
16. Competitive Landscape
16.1 3M Pharmaceuticals
16.2 Acrux
16.3 Agile Therapeutics
16.4 Allergan
16.5 ANI Pharmaceuticals
16.6 Antares Pharma
16.7 Bayer HealthCare Pharmaceuticals
16.8 Corium International
16.9 Chase Pharmaceuticals
16.10 DURECT Corporation
16.11 Endo Pharmaceuticals
16.12 Fempharm
16.13 Hisamitsu Pharmaceutical
16.14 Immune Pharmaceuticals
16.15 Imprimis Pharmaceuticals
16.16 Ipsen Bioscience
16.17 Johnson & Johnson
16.18 LaSalle Laboratories
16.19 Lavipharm-increase
16.20 Luye Pharma
16.21 MINRAD International
16.22 NeurogesX
16.23 Noven Pharmaceuticals
16.24 NuPathe
16.25 Nuvo Research
16.26 Novartis
16.27 Pain Therapeutics
16.28 ProStrakan
16.29 Purdue Pharma
16.30 Sanofi
16.31 Scilex Pharmaceuticals
16.32 Senju Pharmaceutical
16.33 Somerset Pharmaceuticals
16.34 Teikoku Seiyaku
16.35 Therapeutic Discovery Corporation
16.36 Transdermal Delivery Solutions Corp
16.37 UCB
16.38 Xel Pharmaceuticals
16.39 Zosano Pharma
For more information about this report visit https://www.researchandmarkets.com/r/p2jupy
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900